Department of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, United States.
Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, United States.
Semin Cancer Biol. 2019 Apr;55:8-15. doi: 10.1016/j.semcancer.2018.06.004. Epub 2018 Jul 25.
Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer, comprising approximately 75% of all kidney tumors. Recent the Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) studies have significantly advanced the molecular characterization of RCC and facilitated the development of targeted therapies. Such advances have improved the median survival of patients with advanced disease from less than 10 months prior to 2004 to 30 months by 2011. However, approximately 30% of localized ccRCC patients will nevertheless develop recurrence or metastasis after surgical resection of their tumor. Therefore, it is critical to further analyze potential tumor-associated proteins and their profiles during disease progression. Over the past decade, tremendous effort has been focused on the study of molecular pathways, including genomics, transcriptomics, and proteomics in order to identify potential molecular biomarkers, as well as to facilitate early detection, monitor tumor progression and uncover potentially therapeutic targets. In this review, we focus on recent advances in the proteomic analysis of ccRCC, current strategies and challenges, and perspectives in the field. This insight will highlight the discovery of tumor-associated proteins, and their potential clinical impact on personalized precision-based care in ccRCC.
透明细胞肾细胞癌（ccRCC）是最常见的肾癌类型，约占所有肾癌肿瘤的 75%。最近的癌症基因组图谱（TCGA）和国际癌症基因组联合会（ICGC）的研究显著推进了 RCC 的分子特征分析，并促进了靶向治疗的发展。这些进展将 2004 年前晚期疾病患者的中位生存期从不到 10 个月提高到 2011 年的 30 个月。然而，大约 30%的局限性 ccRCC 患者在手术切除肿瘤后仍会复发或转移。因此，进一步分析疾病进展过程中潜在的肿瘤相关蛋白及其特征至关重要。在过去的十年中，人们致力于研究分子途径，包括基因组学、转录组学和蛋白质组学，以识别潜在的分子生物标志物，并促进早期检测、监测肿瘤进展和发现潜在的治疗靶点。在这篇综述中，我们重点介绍了 ccRCC 蛋白质组分析的最新进展、当前的策略和挑战，以及该领域的前景。这一见解将突出发现肿瘤相关蛋白及其在 ccRCC 基于个性化精准医疗中的潜在临床影响。
